How are energy investors positioned?
On Friday, Oppenheimer analysts downgraded LeMaitre Vascular (NASDAQ:LMAT) stock rating from Outperform to Perform. The decision came after the company’s fourth-quarter earnings report, which showed revenues of $55.7 million, a 14% year-over-year organic increase. This figure was consistent with both Oppenheimer’s and the consensus estimates of $55.9 million and $56.0 million, respectively. LeMaitre’s GAAP earnings per share (EPS) also matched expectations at $0.49. The company maintains strong financial fundamentals, with a gross profit margin of 68.34% and an impressive InvestingPro Financial Health Score of 3.3 (GREAT).
The analysts noted that the company had cleared 16 out of 23 product MDR CE marks, with the remaining expected to be cleared by 2025. LeMaitre is also planning to bolster its sales force by adding 13 new sales representatives throughout 2025. These additions are aimed at managing larger North American territories, which currently generate revenues of $1.0-1.2 million per representative, and to support further international expansion. Moreover, LeMaitre received approval for XenoSure in China, with sales projected to commence in the second half of 2025. According to InvestingPro data, the company has demonstrated consistent growth with a five-year revenue CAGR of 13% and maintains a strong balance sheet with a current ratio of 7.74.Want deeper insights? InvestingPro subscribers have access to 14 additional ProTips and comprehensive financial metrics for LMAT.
For fiscal year 2025, LeMaitre introduced revenue guidance in the range of $235.4-242.8 million, compared to Oppenheimer’s and the consensus estimates of $244.5 million and $240.2 million, respectively. The downgrade from Oppenheimer reflects concerns over the long-term sustainability of consistent price increases that have contributed to LeMaitre’s premium valuation. The company is currently trading at a forward price-to-sales (P/S) multiple of 9.4 times FY25 projected sales, which is significantly higher than its small-cap peers at 3.8 times and the overall MedTech industry at 4.0 times.
In light of the fourth-quarter results and the fiscal year 2025 guidance, Oppenheimer has adjusted its estimates accordingly and has also introduced its fiscal year 2026 estimates for LeMaitre. The removal of the $93 price target by Oppenheimer suggests a shift in their outlook on the company’s stock performance potential.
In other recent news, LeMaitre Vascular reported its fourth-quarter 2024 earnings, showcasing a strong performance with earnings per share (EPS) of $0.49, exceeding the forecast of $0.46. The company’s revenue reached $55.7 million, slightly above the projected $55.49 million, marking a 14% year-over-year increase. JMP Securities analyst Daniel Stauder raised the price target for LeMaitre to $113 from $100, maintaining a Market Outperform rating, following the company’s 30% improvement in EPS and a 220 basis point expansion in operating margin. Stauder noted LeMaitre’s consistent financial results and strategic initiatives, including expanding its sales team and securing regulatory approvals, as key factors for the company’s continued success.
LeMaitre’s 2025 guidance projects a revenue midpoint of $239 million, closely aligning with the consensus of $240 million, and an anticipated EPS growth of 16% to $2.24, surpassing analyst expectations. The company is also focusing on international expansion, with plans to launch new products in China and pursue CE mark approvals in Europe. LeMaitre ended the quarter with $300 million in cash and securities, positioning it well for future investments and potential acquisitions. Despite these positive developments, the company’s stock experienced a decline, reflecting broader market volatility and investor concerns over future growth prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.